These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9121269)

  • 1. Hydroxyflutamide may not always be a pure antiandrogen.
    Yeh S; Miyamoto H; Chang C
    Lancet; 1997 Mar; 349(9055):852-3. PubMed ID: 9121269
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.
    Yeh S; Kang HY; Miyamoto H; Nishimura K; Chang HC; Ting HJ; Rahman M; Lin HK; Fujimoto N; Hu YC; Mizokami A; Huang KE; Chang C
    Endocrine; 1999 Oct; 11(2):195-202. PubMed ID: 10709768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
    Yeh S; Lin HK; Kang HY; Thin TH; Lin MF; Chang C
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5458-63. PubMed ID: 10318905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options in patients with hormone-refractory prostate cancer.
    Anand N
    Am J Med; 1996 Feb; 100(2):243-4. PubMed ID: 8629663
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
    Kai L; Levenson AS
    Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of mutant androgen receptors by flutamide.
    Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
    Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
    Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
    Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
    Middleman MN; Lush RM; Figg WD
    Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.
    Hu YC; Yeh S; Yeh SD; Sampson ER; Huang J; Li P; Hsu CL; Ting HJ; Lin HK; Wang L; Kim E; Ni J; Chang C
    J Biol Chem; 2004 Aug; 279(32):33438-46. PubMed ID: 15166229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
    Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.
    Yeh S; Chang C
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5517-21. PubMed ID: 8643607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
    Steinsapir J; Mora G; Muldoon TG
    Biochim Biophys Acta; 1991 Aug; 1094(1):103-12. PubMed ID: 1883848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization.
    Kemppainen JA; Wilson EM
    Urology; 1996 Jul; 48(1):157-63. PubMed ID: 8693644
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
    Berrevoets CA; Veldscholte J; Mulder E
    J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiandrogen in prostate cancer].
    Maeda O; Usami M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract]   [Full Text] [Related]  

  • 18. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.
    Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F
    Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiandrogens prevent stable DNA-binding of the androgen receptor.
    Farla P; Hersmus R; Trapman J; Houtsmuller AB
    J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.